Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

9.44USD
18 Apr 2019
Change (% chg)

$-0.40 (-4.07%)
Prev Close
$9.84
Open
$9.84
Day's High
$9.88
Day's Low
$9.30
Volume
104,292
Avg. Vol
70,528
52-wk High
$20.97
52-wk Low
$9.30

Becker, Marc 

Mr. Marc Becker is the Chief Financial Officer of Concert Pharmaceuticals Inc, effective on January 4, 2018. Mr. Becker joins Concert with a strong track record of strategic and financial experience at high-growth biotechnology companies. Prior to joining Concert, he was Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a commercial stage company with research, clinical, and manufacturing operations, from January 2012 to February 2016. Prior to rEVO, Mr. Becker spent 10 years at Genzyme, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. Mr. Becker began his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

167,720

Roger Tung

3,430,850

Marc Becker

--

Nancy Stuart

1,947,300

Lynette Herscha

--

James Cassella,

1,960,240
As Of  31 Dec 2017